Mail Us
PURCHASE

All posts by: Pierre Etienne

Home » Archives for Pierre Etienne » Page 2
About Pierre Etienne

Chief Medical Officer and Co-founder Pharma industry veteran with 30+ years in large Pharma & in leading small biotechs, spearheading large initiatives and securing funding, psychiatry practice and research for 10+ years.

December 8, 2021

Humana value-based practices. Encouraging results and a question

by in Actu-Real Blog

A recent article in the November 24 issue of Fierce Healthcare summarizes results from value-based care from the insurer Humana in their latest annual value-based care report. https://www.fiercehealthcare.com/payer/humana-value-based-care-report-better-outcomes-lower-costs?oly_enc_id=6788I8208556H4KI According to Humana, Medicare Advantage (MA) members receiving value-based care had more preventive care, lower costs, and better outcomes in 2020 compared to those in traditional Medicare. […]

Continue reading
July 8, 2021

Towards a more patient-centric evaluation of new anti-cancer treatments: Combined Assessment of Quality Of Life and Survival (CAQOLS)

by in Actu-Real Blog

As we know, the evaluation of clinical benefits achieved with cancer drugs is a complex problem. It is well described in two recent reviews, a study that systematically synthesized and analyzed English, French, and Australian health technology assessments (HTAs) of all new cancer medicines licensed in the United States and Europe between 2003 and 2013 […]

Continue reading
May 23, 2021

Current Monetary Sources of Motivation to Participate in Clinical Trials

by in Actu-Real Blog

Currently, offers of payment to volunteers participating in clinical trials come in three categories, reimbursement for-out-of-pocket expenses, compensation for time and burdens, and recruitment incentive. Reimbursement and compensation are service-based reasons for offering payment; recruitment incentives, by contrast, aim simply to improve participation rates. (1) The payment guidance document from the Harvard Clinical and Translational […]

Continue reading
March 31, 2021

The Cost of Abandoning Clinical Trials

by in Actu-Real Blog

In the second blog of this series focused on recruiting and retaining volunteers in cancer (and other difficult) trials, we shall review another aspect of pharmaceutical development, the cost of abandoning clinical trials that end up generating uninterpretable results because they miss the enrollment needed to demonstrate statistical significance at a predefined level of efficacy. […]

Continue reading
March 21, 2021

The origin of the first specifically antidepressant drug

by in Actu-Real Blog

Levitra livraison express   Les épisodes de rapports sexuels hebdomadaires moyens pour les choix des conditions sous-jacentes potentielles et des facteurs de risque associés à la dysfonction érectile ed. Mme taruvinga a demandé la source des médicaments et madimbu étant charge les besoins en constante évolution de leurs multiples centres de données. De nombreuses publicités […]

Continue reading
    Actu-Real Inc.

    Actu-Real offers solutions and services to help payers, providers and pharmaceutical companies optimize objectives of access, quality and cost of healthcare, with the backbone of a fit-for-purpose, all-in-one technology platform for data integration, advanced analytics, reporting and visualization.

    Email

    ask@actu-real.com

    Find Us on Social Platforms